BBIO — BridgeBio Pharma Share News
0.000.00%
Last trade - 00:00- $13.12bn
- $15.77bn
- $502.08m
Media: Sixth Street, KKR provide BridgeBio $1 Billion preferred equity- Bloomberg News
Brief: Bridgebio Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: DKSH Enters Strategic Distribution Partnership With Bridgebio
Brief: Bridgebio Says FDA Accepts NDA For BBP-418 With Priority Review For LGMD2I/R9
U.S. RESEARCH ROUNDUP-Apollo, Phillips 66, Valero Energy
Brief: Bridgebio Submits NDA To FDA For Encaleret For Individuals Living With ADH1
Brief: Acoramidis Continues To Demonstrate Disease-Modifying Effects In ATTR-CM
Brief: Bridgebio Pharma reports inducement grants under Nasdaq listing rule 5635(C)(4)
Brief: BridgeBio Pharma Inc Files For Mixed Shelf Size Not Disclosed - SEC Filing
BridgeBio Pharma Q1 revenue rises 67% on Attruby sales
Brief: BridgeBio Pharma Q1 Net Income USD -166.555 Million
U.S. RESEARCH ROUNDUP-Coca-Cola Co, Mondelez, Zeta Global Holdings
U.S. STOCKS ON THE MOVE-AxoGen, energy companies, Corning
BridgeBio slips as Pfizer patent deal disappoints investors
Brief: Bridgebio Submits NDA To FDA For Bbp-418 For Individuals Living With Lgmd2i/R9
Brief: Bridgebio Pharma Plans To Submit NDA For BBP-418 To FDA In H1 2026
U.S. RESEARCH ROUNDUP-Adobe, Caseys General Stores, Fedex
Ascendis wins U.S. approval for therapy for children with dwarfism (updated)
Ascendis wins U.S. approval for therapy for children with dwarfism